bs-11337R-Cy3 [Conjugated Primary Antibody]
C1QC/C1QG Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: C1QC/C1QG

Immunogen Range: 81-180/245


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human C1QC

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

C1q, a subcomponent of the classical complement pathway, is composed of nine subunits that mediate classical complement activation and thereby play an important role in the immune response. Six of these subunits are disulfide-linked dimers of chains A and B, while three of these subunits, designated C1q-A through C1q-C, are disulfide-linked dimers of chain C. The presence of receptors for C1q on effector cells modulates its activity, which may be antibody-dependent or independent. Macrophages are the primary source of C1q, while anti-inflammatory drugs as well as cytokines differentially regulate expression of the mRNA, as well as the protein. However, its ability to modulate the interaction of platelets with collagen and immune complexes suggests C1q influences homeostasis as well as other immune activities, and perhaps thrombotic complications resulting from immune injury. Defects in C1q-A, C1q-B and C1q-C cause inactivation of the classical pathway, leading to a rare genetic disorder characterized by lupus-like symptoms.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 23


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Dog
Horse
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Wu Yutong. et al. Osteoclast-Derived Apoptotic Bodies Inhibit Naive Cd8<sup> </sup> T Cell Activation via Siglec15 Promoting Breast Cancer Secondary Metastasis. Cell Reports Medicine. 2022 Nov 03Read more>>
  • Peng Zhiwei. et al. Interactions between MFAP5?+?fibroblasts and tumor-infiltrating myeloid cells shape the malignant microenvironment of colorectal cancer. J TRANSL MED. 2023 Dec;21(1):1-2Read more>>